. 2016 Apr 13;6:19612. doi: 10.1038/srep19612

Table 4. Adjusted associations between cinacalcet use and clinical outcomes in patients with baseline iPTH ≥300 pg/ml, computed using marginal structural models^a.

	Adjusted RR	95% CI	p-value
Death due to any cause^b	0.75	0.55–1.03	0.073
Death due to cardiovascular disease^b	0.90	0.56–1.47	0.683
Cardiovascular hospitalization or death^c	0.71	0.53–0.94	0.016

RR: incidence rate ratio, 95% CI: 95% confidence interval.

^aEstimated from weighted Poisson regression models. To calculate weight, probability of initiating cinacalcet was predicted by age, sex, vintage, primary renal disease, cardiovascular disease, lung disease, liver disease, malignancy, parathyroidectomy, time-varying value of VDRA, phosphate binder, serum Ca, serum inorganic Phosphorus, serum iPTH, dialysate Ca, Kt/V, serum Alb, BMI, Hgb, interaction terms of treatment variables and MBD variables, and visit number.

^bEstimated from case-cohort studies.

^cEstimated from cohort study.

Table 4. Adjusted associations between cinacalcet use and clinical outcomes in patients with baseline iPTH ≥300 pg/ml, computed using marginal structural modelsa.

Table 4. Adjusted associations between cinacalcet use and clinical outcomes in patients with baseline iPTH ≥300 pg/ml, computed using marginal structural models^a.